科研项目：

1、国家科技重大专项，联合应用自动化痰涂片镜检系统和熔解曲线耐药基因检测技术诊断耐药肺结核的研究，2018.12-2021.12，1029.6万元，已结题，主持

2、广州市卫健委临床高新、重大和特色技术项目，基于结核病新型特异性细胞因子检测技术诊断菌阴结核病，2020.01-2023.06，50万元，已结题，主持

3、广州市科技计划重点项目，分枝杆菌病伴随诊断方案的临床应用研究，2023.04-202503，200万元，在研，主持

4、广州市重点实验室，广州市结核病研究重点实验室，2023.04—202503，700万元，在研，参与

代表性学术论文：

1、Accuracy of the InnowaveDX MTB/RIF test for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre study. 2023 Emerg Microbes Infect. (IF: 13.2, II区, 共同通讯)

2、Effect of Mixed Infections with Mycobacterium tuberculosis and Nontuberculous Mycobacteria on Diagnosis of Multidrug-Resistant Tuberculosis: A Retrospective Multicentre Study in China. 2022 Infect Drug Resist. (3.9, II区, 共同第一)

3、Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study. 2021J Infect. (28.2, I区, 一作排第一)

4、Combined IFN-γ and IL-2 release assay for detect active pulmonary tuberculosis: a prospective multicentre diagnostic study in China. 2021 J Transl Med. (7.4, II区, 一作排第一)

5、An automated smear microscopy system to diagnose tuberculosis in a high-burden setting. 2019 Clin Microbiol Infect. (14.2,I区, 一作排第一)

6、Rapid Identification of　Clinically Relevant Mycobacterium Species by Multicolor Melting Curve Analysis.2019 J Clin Microbiol. (9.4, II区, 共同通讯)

7、Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. 2019 Clin Microbiol Infect. (14.2, I区, 共同第一)

8、Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China, 2013-2016. 2018BMC Pulm Med. (3.1, III区, 一作排第一)

9、Highly Sensitive Detection of Isoniazid Heteroresistance in Mycobacterium tuberculosis by DeepMelt Assay. 2018 J Clin Microbiol. (9.4, II区, 共同第一)

10、结核病病原学分子诊断专家共识. 2018 中华结核和呼吸杂志. (最后通讯)